

Enterprise One Pain Management Service

Executive Summary – 1 July 2022 to 30 June 2023



Patient profile

Enterprise One received 328 completed referral questionnaires in this period (all services, n = 20953)

Demographic information	Your service	All services
Sex (female)	52.4%	58.5%
Average age (years)	46.8	50.5
Interpreter required	0.6%	3.2%
Communication assistance required	3.1%	7.7%
Living in highest disadvantage area	17.2%	21.0%
Aboriginal and/or Torres Strait Islander	6.9%	5.5%

Services provided

	Your service	All services
Episodes of care started	348	16452
Waiting time* (median days)	52	56
Patients participating in education/orientation programs	46	4469
Patients assessed by multidisciplinary team	0	2204
No. of treatment pathways started	355	11676
Treatment pathway type (%)		
- Group program	43.1	24.5
- Individual	51.3	53.4
- Concurrent	5.6	15.5
- Other	0.0	6.6
Episodes of care ended	161	10626

* Days from referral received to episode start

Clinical characteristics	Your service	All services
Average number of pain sites	4.0	4.3
Average number of comorbidities	1.9	2.6
% using opioids > 2 days/week	31.4	41.0
Average oMEDD (mg)	33.5	45.5
Average number of drug groups used	1.8	2.0
% outside normal BMI range	80.2	75.3
% experiencing pain >5 years	21.9	42.2
% unemployed due to pain	39.5	36.9
Pain severity	5.7	6.2
Pain interference	6.7	6.9
	Mild / Moderate / Severe	
Depression	18.5	18.8
Anxiety	11.9	12.9
Stress	20.1	19.8
	Normal / Mild / Moderate / Severe / Extremely severe	
Pain catastrophising	24.8	28.1
	Mild / High / Severe	
Pain self-efficacy	21.9	21.2
	Minimal / Mild / Moderate / Severe impairment	

Collection of patient outcomes

A detailed summary of outcome collection rates at episode end and at post-episode follow-up can be found in the appendices of your report.

Benchmark & indicator summary

Benchmarks (BM)	BM target	Your service			All services		
		Patient outcomes included (n)	Positive outcomes* (%)	BM met?	Patient outcomes included (n)	Positive outcomes* (%)	Services met BM
Average pain <i>Patients with moderate or severe average pain at referral who have made a clinically significant improvement at episode end</i>	40%	90	40.0%	Yes	2730	30.4%	11/56
Pain interference <i>Patients with moderate or severe pain interference at referral who have made a clinically significant improvement at episode end</i>	70%	103	64.1%	No	3038	59.8%	13/58
Depression <i>Patients with moderate, severe or extremely severe depression at referral who have made a clinically significant improvement at episode end</i>	70%	71	64.8%	No	2085	55.6%	9/53
Anxiety <i>Patients with moderate, severe or extremely severe anxiety at referral who have made a clinically significant improvement at episode end</i>	50%	59	45.8%	No	1837	44.3%	14/45
Stress <i>Patients with moderate, severe or extremely severe stress at referral who have made a clinically significant improvement at episode end</i>	60%	59	55.9%	No	1646	58.4%	19/43
Pain catastrophising <i>Patients with high or severe pain catastrophising at referral who have made a clinically significant improvement at episode end</i>	70%	81	71.6%	Yes	2288	57.6%	14/51
Pain self-efficacy <i>Patients with impaired self-efficacy (moderate or severe) at referral who have made a clinically significant improvement at episode end</i>	60%	93	48.4%	No	2424	50.7%	16/56
Opioid use <i>Patients taking opioids at referral who report a reduction in their oMEDD[†] of at least 50% at episode end</i>	60%^{††}	46	45.7%	No	1273	56.7%	16/37
Opioid use (high dose) <i>Patients reporting 40mg or more oMEDD[†] at referral who report a reduction of at least 50% at episode end</i>	60%	13	46.2%	No	437	52.6%	6/12
Indicators							
Wait time – 3 months <i>Episodes starting within 3 months of the referral being received</i>	-	345	84.1%	-	15792	64.1%	-
Wait time – 8 weeks <i>Episodes starting within 8 weeks of the referral being received</i>	-	345	56.8%	-	15792	50.0%	-

* Positive outcomes describes the percentage of patients making a clinically significant improvement, or reducing oMEDD by 50% or having their episode start within 3 months/8 weeks where relevant

† oMEDD = oral morphine equivalent daily dose

†† The all-dose opioid use benchmark has been raised from 50% to 60% from the 2022 mid-year report onwards

- is shown for the benchmarks and indicators where less than 10 outcomes are included